
|Articles|September 1, 2003
Using bisphosphonates to treat PCa-related bone events
Author(s)E. David Crawford, MD, Shandra Wilson, MD
Prostate cancer is the most prevalent non-cutaneous cancer diagnosed in men today, still accounting for a significant amount of morbidity and mortality in spite of increased screening efforts and advances in treatment.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
4
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
5















